Noticias y Actividades de Actinium Pharmaceuticals

Actinium Pharmaceuticals es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Actinium Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización ATNM (US).

Ver el organigrama con sus 18 ejecutivos principales

Biografías más buscadas en Actinium Pharmaceuticals

• Sandesh Seth, Chairman of the Board and Chief Executive Officer
• David Nicholson, Lead Independent Director
• Richard Steinhart, Director

Recientes movimientos de ejecutivos en Actinium Pharmaceuticals

• June Almenoff, se ha incorporado a la empresa como Director  (noticia publicada el 5 de noviembre de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Actinium Pharmaceuticals.

Actinium Pharmaceuticals tiene 1.824 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Roche (Suiza).

Popular M&A news in Farmacia

• Cyclo Therapeutics ha Rafael Holdings adquirido (publicado el 28 de abril de 2025).
• Chimerix and Chimerix have merged  (publicado el 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Jean-Michel Demeure - Vice President, Finance Global Operations en Sanofi

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Actinium Pharmaceuticals

• Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today :: Actinium Pharmaceuticals, Inc. (ATNM)
• Press Releases :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives :: Actinium Pharmaceut
• Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical
• Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia :: Actinium Pharmaceuticals, Inc. (ATNM)
• View more press releases Close

Redes sociales sobre Actinium Pharmaceuticals

• Actinium Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Actinium Pharmaceuticals en LinkedIn, Twitter y YouTube